Donglin Sun | Prostate Cancer | Best Researcher Award

Posted on by Pencis

Dr. Donglin Sun | Prostate Cancer | Best Researcher Award

Southern Medical University | China

AUTHOR PROFILE

Scopus

🔬SUN DONGLIN – MEDICAL DOCTOR IN ONCOLOGY 

📚EARLY ACADEMIC PURSUITS 

Sun Donglin began his academic journey at No.1 Middle School of Fuyang, Anhui Province (2005-2008). His strong foundation in science led him to pursue a Bachelor’s Degree in Clinical Medicine at Bengbu Medical College (2008-2013), where he developed a keen interest in oncology. His dedication and passion for medical research culminated in a PhD in Oncology through the Master-Doctor Continuous Program at the Affiliated Cancer Hospital of Guangzhou Medical University (2018-2023). He was recognized as an “Outstanding Graduate Student” and “Excellent Graduate”, a testament to his academic excellence and research contributions.

🏥PROFESSIONAL ENDEAVORS 

Sun Donglin’s clinical training and professional career reflect a steady progression in expertise:

  • 2013 – 2016: Surgical Resident, Third Affiliated Hospital of Sun Yat-sen University – Gained hands-on experience in surgical oncology.
  • 2016 – 2018: Urology Resident Physician, Shenzhen Hospital of Southern Medical University – Developed a specialization in urological oncology.
  • 2023 – Present: Urology Associate Chief Physician, Shenzhen Hospital of Southern Medical University – Achieved Associate Chief Physician Certification in 2020, demonstrating his leadership in urologic oncology and clinical excellence.

🔍RESEARCH FOCUS 

Sun Donglin’s research focuses on two critical areas in oncology:

  1. Mechanisms of Non-Canonical NF-κB Signaling in Renal Fibrosis – Investigating how alternative pathways of NF-κB contribute to fibrosis, which has significant implications for kidney disease treatments.
  2. Drug Resistance Mechanisms in Prostate Cancer – Exploring molecular resistance pathways in prostate cancer to enhance therapeutic strategies and overcome treatment barriers.

💡CONTRIBUTIONS TO SCIENTIFIC RESEARCH 

Sun Donglin has led and participated in several high-impact research projects:

  • Principal Investigator:

    • National Natural Science Foundation of China (Youth Program) – 300,000 RMB (2025-2027) (Approval No.: 82400789)
    • Guangdong Provincial Medical Science and Technology Research Fund – 10,000 RMB (2024-2026) (Approval No.: A2024317)
    • Southern Medical University National Natural Science Foundation Cultivation Program – 100,000 RMB (2024-2026) (Approval No.: 23H3AGZR02)

  • Key Participant in Major Research Projects:

    • National Natural Science Foundation of China Major Research Program Cultivation Project – 680,000 RMB (2020-2022) (Approval No.: 91949102)
    • National Natural Science Foundation of China General Program – 570,000 RMB (2019-2022) (Approval No.: 81874095)

🌍IMPACT AND INFLUENCE 🌍

Sun Donglin’s research has contributed to a deeper understanding of renal fibrosis mechanisms and drug resistance in prostate cancer. His work has the potential to improve therapeutic interventions and patient outcomes, particularly in treatment-resistant prostate cancer cases. His collaborations in major national projects highlight his role as an emerging leader in oncological research.

🏅ACADEMIC CITES AND RECOGNITION 

  • Recognized as an Outstanding Graduate Student and Excellent Graduate during his PhD.
  • His research findings are gaining recognition in top-tier oncology journals, further solidifying his influence in the field.
  • Contributions to multi-million RMB-funded research projects, showcasing his ability to secure competitive grants.

🌱LEGACY AND FUTURE CONTRIBUTIONS 

Sun Donglin’s work will shape the future of oncology therapeutics and urological oncology. His research on non-canonical NF-κB signaling could unlock new pathways for renal fibrosis treatment, while his studies on prostate cancer drug resistance could lead to novel therapeutic strategies.

Moving forward, he aims to:
✅ Expand research collaborations internationally to enhance the impact of his studies.
✅ Develop translational therapies targeting NF-κB signaling in fibrosis and prostate cancer.
✅ Mentor young oncologists and researchers to foster the next generation of medical scientists.

🌍CONCLUSION 

Dr. Sun Donglin is a rising leader in oncology research and urological oncology, with a strong foundation in both clinical practice and scientific innovation. His expertise in non-canonical NF-κB signaling in renal fibrosis and drug resistance in prostate cancer has positioned him as a key contributor to the advancement of cancer therapeutics.

 

📊🔬NOTABLE PUBLICATION:
  • Title: Serum RelB is correlated with renal fibrosis and predicts chronic kidney disease progression
    Authors: Sun, D., Xie, N., Wang, X., Wu, W., Li, X. Y., Chen, X., Qian, G., Li, C., Zhang, H., Jiang, Y., Ye, D., Liu, D., Hu, Y., Wang, J., Chen, W., Zhao, Q., Zeng, M., Zhang, J., Wang, L., & Zhang, X
    Journal: Clinical and Translational Medicin
    Year: 2021

 

  • Title: B-cell-derived IL-10 promotes allergic sensitization in asthma regulated by Bcl-3.
    Authors: Qian, G., Jiang, W., Sun, D., Sun, Z., Chen, A., Fang, H., Wang, J., Liu, Y., Yin, Z., Wei, H., Fang, H., & Zhang, X.
    Journal: Cellular & Molecular Immunology
    Year: 2023

 

  • Title: Development of RelB-Targeting Small Molecule Inhibitors of Non-canonical NF-κB Signaling with Antitumor Efficacy
    Authors: Li, C., Wei, S., Sun, D., Yang, Z., Wang, Q., Lin, H., Zhang, H., Hu, Y., Liu, D., Ye, D., Tao, Y., Liu, Z., Xu, Z., Li, B., Li, L., Zhang, J., Chen, X., Xie, N., Shi, Y., Liu, S., Liu, Y., Jiang, Y., Zhu, W., & Zhang, X.
    Journal: Molecular Therapy
    Year: 2025

 

  • Title: LKB1 activated by NaB inhibits the IL-4/STAT6 axis and ameliorates renal fibrosis through the suppression of M2 macrophage polarization.
    Authors: Liang, W., Wu, H., Long, Q., Lin, H., Lv, X., Ma, W., Wu, T., Ai, L., Zheng, Q., Guo, J., Chen, X., Guo, J., & Sun, D..
    Journal: Life Sciences
    Year: 2025

 

  • Title: Integrative analysis of potential diagnostic markers and therapeutic targets for glomerulus-associated diabetic nephropathy based on cellular senescence
    Authors: Sun, D., Wei, S., Wang, D., Zeng, M., Mo, Y., Li, H., Liang, C., Li, L., Zhang, J. W., & Wang, L
    Journal: Frontiers in Immunology
    Year: 2023

Mr.Christopher Olowosoke – Targeted Cancer Therapy – Best Researcher Award

Posted on by Pencis

Mr.Christopher Olowosoke - Targeted Cancer Therapy - Best Researcher Award

Federal University of Technology Akure - Nigeria

AUTHOR PROFILE

Scopus

EARLY ACADEMIC PURSUITS

Christopher Busayo Olowosoke embarked on his academic journey with a focus on biotechnology. His dedication to academic excellence was evident during his West African Senior School Certificate Examination at Isefun Community Senior Secondary School, Lagos State, Nigeria, where he achieved a grade of Distinction in the Science stream. This early success set the stage for his future pursuits in the field of biotechnology and information technology.

PROFESSIONAL ENDEAVORS

With a passion for biotechnology and an interest in the chemistry of natural products and pharmacology, Christopher pursued his first degree at the Federal University of Technology, Akure, Ondo State, Nigeria. Graduating with an outstanding grade of 4.73/5.00 in Biotechnology in 2020, he showcased his commitment to academic excellence. His undergraduate thesis, "Identification of pungency-associated genes in some indigenous Nigerian hot pepper varieties," demonstrated his engagement with cutting-edge research.

CONTRIBUTIONS AND RESEARCH FOCUS ON TARGETED CANCER THERAPY

As a Student Research Assistant at the Federal University of Technology, Akure, Christopher actively contributed to research in the Departments of Biochemistry, Biotechnology, and Microbiology from 2017 to 2021. His involvement in in vivo, in vitro, and in silico procedures for diabetes and  targeted cancer therapy underscored his commitment to addressing metabolic and cellular proliferation dysregulation, aligning with Sustainable Development Goal 3 (SDG 3). Additionally, his work on the phyto-treatment of diabetes using Andrographic paniculata showcased his dedication to innovative therapeutic approaches.

IMPACT AND INFLUENCE

Christopher's impact extended beyond the laboratory. As a Laboratory Research Assistant at Chrisland University Biotechnology Department from 2022 to the present, he played a pivotal role in organizing practical sessions and providing training in bioinformatics and molecular biology for undergraduates. His leadership as the Founder of B.Khrease Academic Consult since 2018 highlights his commitment to facilitating student projects, mentorship, and collaboration with academic experts.

ACADEMIC CITES

Christopher's research contributions are recognized through his publications. His paper titled "Multiregulator of EZH2-PPARs Therapeutic Targets" was published in Applied Biochemistry and Biotechnology in 2023. This publication addresses critical aspects of pancreatic insulin production and cancer dysregulation. The link to his full publication list on ResearchGate (https://www.researchgate.net/profile/Christopher-Olowosoke/research) reflects his ongoing scholarly pursuits.

LEGACY AND FUTURE CONTRIBUTIONS

Christopher's legacy includes leadership roles, such as being the Founder of B.Khrease Academic Consult and serving as the Promotional and Development Committee Head at the Institute of Bioinformatics and Molecular Therapeutic (IBMT) since 2021. His active participation in conferences, workshops, and professional webinars, as well as affiliations with prestigious societies, showcases his commitment to staying at the forefront of biotechnological advancements.

AWARDS/GRANT

Christopher's achievements are acknowledged through various awards and grants, including being a beneficiary of the American Society for Nutrition Early Career Professional Mentoring Program in 2023 and securing the second position in the Peeref International Best Poster Presentation in the same year. His involvement in securing the TETFUND Grant Award for the Biotechnology Department in 2022 and the UNESCO-ICB Scholarship in 2020 further demonstrates his capacity to contribute significantly to his field.

NOTABLE PUBLICATION

Multi-regulator of EZH2-PPARs Therapeutic Targets: A Hallmark for Prospective Restoration of Pancreatic Insulin Production and Cancer Dysregulation.